Congress Materials

Medical Information
Saudi Arabia
 

This medical Information website is intended only for Healthcare Professionals in the Kingdom of Saudi Arabia. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

This content is intended for Healthcare professionals in Saudi Arabia. Would you like to proceed?

I am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
SelectI am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
I am not a healthcare professionalNo, go back to the patient portal
SelectI am not a healthcare professionalNo, go back to the patient portal
Non-Saudi Arabia residents click here.
The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Grimm MO, Oya M, Choueiri TK, Schmidinger M, Quinn DI, Gravis-Mescam G, Verzoni E, Van den Eertwegh AJM, di Pietro A, Mariani M, Wang J, Thomaidou D, Albiges L September 16, 2021 ESMO 2021 Renal Cell Carcinoma

Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib or sunitinib: results from JAVELIN Renal 101

View Presentation
Poster
Nathan P, Muazzam I, Frazer R, Sharma A, Hickey J, Ritchie AR February 18, 2022 ASCO GU 2022 Renal Cell Carcinoma

Avelumab plus axitinib in advanced renal cell carcinoma (aRCC): 12-month interim results from a real-world observational study in the UK

View Presentation View Abstract Plain Language Summary
Poster
Strambi A, Jakobsson M, Nilsson F, Arpegård J, Dalén J February 18, 2022 ASCO GU 2022 Renal Cell Carcinoma

Real-World Experience of Axitinib as Second-line Treatment in Metastatic Renal Cell Carcinoma: Analysis of the Swedish Population

View Presentation
Poster
Zakharia Y, Thomaidou D, Li B, Siu G, Levin R, Vlahiotis A, Rao D, Zanotti G February 18, 2022 ASCO GU 2022 Renal Cell Carcinoma

Real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States

View Presentation